Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.83 Insider Own58.20% Shs Outstand130.33M Perf Week-4.59%
Market Cap5.13B Forward P/E- EPS next Y-1.85 Insider Trans1.68% Shs Float60.74M Perf Month-3.05%
Income-243.45M PEG- EPS next Q-0.43 Inst Own46.32% Short Float14.84% Perf Quarter-7.69%
Sales0.00M P/S- EPS this Y-3.95% Inst Trans5.05% Short Ratio6.04 Perf Half Y58.08%
Book/sh4.68 P/B7.54 EPS next Y-3.92% ROA-41.70% Short Interest9.01M Perf Year101.71%
Cash/sh4.76 P/C7.42 EPS next 5Y3.69% ROE-44.51% 52W Range14.05 - 45.58 Perf YTD-16.21%
Dividend Est.- P/FCF- EPS past 5Y- ROI-35.84% 52W High-22.55% Beta0.72
Dividend TTM- Quick Ratio22.14 Sales past 5Y0.00% Gross Margin- 52W Low151.25% ATR (14)1.79
Dividend Ex-Date- Current Ratio22.14 EPS Y/Y TTM-10.48% Oper. Margin0.00% RSI (14)39.97 Volatility5.52% 4.63%
Employees164 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.06 Target Price50.73
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q27.65% Payout- Rel Volume0.67 Prev Close35.37
Sales Surprise- EPS Surprise33.09% Sales Q/Q- EarningsFeb 12 BMO Avg Volume1.49M Price35.30
SMA20-3.67% SMA50-9.66% SMA20017.59% Trades Volume995,780 Change-0.20%
Date Action Analyst Rating Change Price Target Change
Feb-20-24Initiated JP Morgan Overweight $51
Feb-15-24Initiated Wolfe Research Outperform $55
Dec-12-23Initiated Deutsche Bank Buy $50
Oct-13-23Upgrade UBS Neutral → Buy $18 → $55
Sep-26-23Upgrade Raymond James Mkt Perform → Outperform $40
May-01-23Initiated BofA Securities Buy $26
Apr-25-23Initiated Citigroup Buy $28
Mar-31-23Initiated Piper Sandler Overweight $28
Mar-30-23Initiated Stifel Buy $28
Feb-15-23Initiated Cantor Fitzgerald Overweight $30
Feb-23-24 11:22PM
Feb-14-24 04:35AM
Feb-13-24 07:26AM
Feb-12-24 07:00AM
02:38PM Loading…
Feb-06-24 02:38PM
Jan-22-24 06:07AM
Jan-19-24 04:39PM
Jan-13-24 03:02AM
Jan-03-24 08:00AM
Dec-26-23 10:01AM
Dec-21-23 04:09PM
04:30PM Loading…
Dec-20-23 04:30PM
Dec-19-23 10:16AM
Dec-01-23 01:01AM
Nov-29-23 10:22AM
Nov-28-23 07:00AM
Nov-25-23 11:03AM
Nov-14-23 12:30AM
Nov-13-23 08:00AM
Nov-10-23 07:19AM
Nov-09-23 08:17AM
Oct-27-23 11:02PM
Oct-13-23 09:50AM
11:01PM Loading…
Oct-11-23 11:01PM
Oct-07-23 01:00AM
Oct-05-23 03:01AM
Oct-02-23 04:52PM
Sep-28-23 09:58AM
Sep-27-23 11:41PM
Sep-26-23 05:00PM
Sep-25-23 11:01PM
Aug-17-23 09:31AM
Aug-12-23 08:25AM
Aug-11-23 11:20AM
Aug-10-23 07:00AM
Aug-09-23 06:26AM
Aug-01-23 10:00AM
Jul-03-23 09:00AM
Jul-01-23 09:00AM
Jun-29-23 01:42AM
Jun-21-23 11:30AM
May-23-23 09:48AM
May-22-23 07:00AM
Apr-05-23 01:45PM
Feb-15-23 01:14PM
Feb-03-23 07:00AM
Dec-29-22 11:04AM
Dec-19-22 07:53AM
Dec-16-22 08:06AM
Dec-15-22 09:40AM
Dec-12-22 03:44PM
Nov-25-22 09:40AM
Nov-24-22 11:04AM
Nov-17-22 10:38AM
Nov-09-22 09:40AM
Nov-07-22 01:34PM
Nov-04-22 07:00AM
Oct-20-22 01:56PM
Oct-09-22 10:57AM
Oct-06-22 03:52PM
Oct-04-22 08:45AM
Sep-29-22 02:36PM
Sep-28-22 10:45AM
Sep-26-22 04:41PM
Sep-21-22 08:00AM
Sep-09-22 08:00AM
Sep-07-22 07:11AM
Sep-06-22 09:26AM
Sep-02-22 12:00PM
Aug-30-22 09:55AM
Aug-24-22 08:00AM
Aug-18-22 11:00AM
Aug-17-22 12:27PM
Aug-15-22 10:40AM
Aug-10-22 09:55AM
Aug-08-22 09:34AM
Aug-05-22 07:00AM
Jul-08-22 11:30AM
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Salzmann PeterChief Executive OfficerFeb 22Sale36.1513,454486,362931,231Feb 23 04:11 PM
Barnett Eva ReneeChief Financial OfficerFeb 22Sale36.152,930105,920320,420Feb 23 04:21 PM
Macias William L.Chief Medical OfficerFeb 22Sale36.152,22180,289330,952Feb 23 04:16 PM
Butchko Julia G.Chief Development OfficerFeb 22Sale36.152,14677,578407,817Feb 23 04:14 PM
Levine Mark S.Chief Legal OfficerFeb 22Sale36.152,13477,144301,968Feb 23 04:18 PM
Geffner MichaelChief Medical OfficerJan 26Sale37.9210,101383,01289,899Jan 29 04:11 PM
Levine Mark S.Chief Legal OfficerJan 26Sale37.923,027114,778304,102Jan 29 04:12 PM
Macias William L.Chief Medical OfficerJan 18Sale41.0342417,397333,173Jan 19 04:04 PM
Barnett Eva ReneeChief Financial OfficerJan 11Sale41.833,515147,023323,350Jan 12 04:34 PM
Salzmann PeterChief Executive OfficerJan 05Sale38.593,824147,568944,685Jan 09 04:18 PM
Butchko Julia G.Chief Development OfficerJan 05Sale38.591,29750,051409,963Jan 09 04:20 PM
MIGAUSKY GEORGE VDirectorDec 01Sale39.7312,700504,567109,808Dec 05 04:25 PM
Fromkin Andrew J.DirectorDec 01Sale39.7312,350490,69788,658Dec 05 04:30 PM
Pande AtulDirectorDec 01Sale39.7312,350490,66783,158Dec 05 04:28 PM
Salzmann PeterChief Executive OfficerNov 22Sale32.7816,217531,581948,509Nov 24 02:55 PM
Barnett Eva ReneeChief Financial OfficerNov 22Sale32.784,055132,920326,865Nov 24 02:51 PM
Butchko Julia G.Chief Development OfficerNov 22Sale32.783,265107,024411,260Nov 24 02:47 PM
Macias William L.Chief Medical OfficerNov 22Sale32.783,265107,024333,597Nov 24 02:45 PM
Levine Mark S.Chief Legal OfficerNov 22Sale32.783,252106,598307,129Nov 24 02:41 PM
Levine Mark S.Chief Legal OfficerOct 25Sale34.664,107142,349310,381Oct 27 04:04 PM
Macias William L.Chief Medical OfficerOct 19Sale36.8053019,504336,862Oct 20 04:06 PM
Barnett Eva ReneeChief Financial OfficerOct 10Sale36.924,557168,244330,920Oct 11 04:11 PM
Salzmann PeterChief Executive OfficerOct 05Sale36.245,239189,887964,726Oct 06 05:10 PM
Butchko Julia G.Chief Development OfficerOct 05Sale36.241,73562,885414,525Oct 06 05:15 PM
Roivant Sciences Ltd.DirectorOct 02Buy38.001,526,31658,000,00879,805,331Oct 04 05:15 PM
Salzmann PeterChief Executive OfficerAug 30Sale22.0256,7741,250,338969,965Sep 01 04:08 PM
Barnett Eva ReneeChief Financial OfficerAug 24Sale20.3014,386292,036335,477Aug 25 05:03 PM
Butchko Julia G.Chief Development OfficerAug 24Sale20.3012,333250,360416,260Aug 25 05:00 PM
Macias William L.Chief Medical OfficerAug 24Sale20.3012,333250,360337,392Aug 25 04:57 PM
Levine Mark S.Chief Legal OfficerAug 24Sale20.3012,286249,406314,488Aug 25 05:05 PM
Salzmann PeterChief Executive OfficerAug 14Sale21.42103,0582,207,1781,026,739Aug 16 04:11 PM
Salzmann PeterChief Executive OfficerAug 07Sale21.73101,3392,202,0961,129,797Aug 08 04:44 PM
Levine Mark S.Chief Legal OfficerJul 26Sale21.633,91784,725326,774Jul 27 04:33 PM
Barnett Eva ReneeChief Financial OfficerJul 19Sale24.942,72567,962349,863Jul 20 04:35 PM
Macias William L.Chief Medical OfficerJul 19Sale24.9442610,624349,725Jul 20 04:37 PM
Salzmann PeterChief Executive OfficerJul 12Sale19.733,23363,7871,231,136Jul 13 05:11 PM
Butchko Julia G.Chief Development OfficerJul 12Sale19.731,47029,003428,593Jul 13 05:10 PM
Levine Mark S.Chief Legal OfficerApr 25Sale16.292,63342,892330,691Apr 26 04:08 PM
Macias William L.Chief Medical OfficerApr 25Sale16.295098,292350,151Apr 26 04:12 PM
Barnett Eva ReneeChief Financial OfficerApr 18Sale15.273,42352,269352,588Apr 19 04:15 PM
Salzmann PeterChief Executive OfficerApr 18Sale15.273,39551,8421,234,369Apr 19 04:09 PM
Butchko Julia G.Chief Development OfficerApr 18Sale15.271,54423,577430,063Apr 19 04:12 PM